Taysha Gene Therapies
NASDAQ: TSHATexas, US · Founded 2019 · Delaware corporation · 134 employees on LinkedIn · 7 known investors
Find your way into Taysha Gene Therapies
139 people in our graph share verified history with the Taysha Gene Therapies team — schools, employers, funds. One of them is your warm intro.
Jovelyn Castellanosunlockedknows R.A. Session II · together at UT Southwestern Medical Center (overlapped)
×8knows the team · via University of Houston
×2knows the team · via UT Southwestern Medical Center
knows the team · via John Carroll University
Taysha Gene Therapies develops and commercializes gene therapies for monogenic diseases of the central nervous system, serving patients with rare and larger CNS conditions. Its lead clinical program targets Rett syndrome, alongside a broader pipeline of CNS programs.
Founders & leadership
Taysha Gene Therapies was founded in 2019 by R.A. Session II.
RS
R.A. Session IIinFounder & Member Board of Directors2020–2023R.A. Session II co-founded Taysha Gene Therapies and served as its CEO and president. He has over 20 years of experience in life sciences, including prior roles as Chief Business Officer at BridgeBio's gene therapy subsidiaries and Senior Vice President of Corporate Strategy and Business Development at AveXis.
SP
Sean P. NolaninChief Executive OfficerNolan previously led AveXis Inc. as President and CEO from 2015 to 2018, and held senior roles including Chief Business Officer at InterMune, Chief Commercial Officer at Reata Pharmaceuticals, and President of Lundbeck Inc., the company's US affiliate formerly known as Ovation Pharmaceuticals. His earlier work at Lundbeck spanned product development, global project management, and commercial integration following the Ovation acquisition.
Board
PB
Investors · 7
GV (Google Ventures)Mountain View · $250K – $50M
BairdreportedMilwaukee
Goldman SachsreportedNew York
JefferiesreportedNew York
PBM CapitalreportedCharlottesvillevia Paul B. Manning · board
Also in the syndicate · 2
CantorPiper Sandler
Funding
SEC filings, press & company announcements$494M disclosed across 5 of 6 rounds · 2020–2026
- $200MraisedJun 2026 · 2 sources
Baird (lead), Cantor, Goldman Sachs & Co. LLC, Jefferies, Piper Sandler
Source ↗
▶$150MraisedAug 2023 · 42 investors · BiotechnologyRule 506(b)
▶$150MraisedAug 2023 · 42 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Phillip DonenbergDirector
- Sean P. NolanExecutive Officer, Director
- Laura Sepp-LorenzinoDirector
- Sean StalfortDirector
- Kamran AlamExecutive Officer
- Kathleen ReapeDirector
- Sukumar NagendranExecutive Officer, Director
- Offering amount
- $150M
- Amount sold
- $150M
- Finders' fees
- $9M
- Placement agents
- Jefferies LLC
- First sale
- Aug 2023
- Incorporated
- Corporation, Delaware, 2019
- Federal exemptions
- 06b
▶$30MraisedNov 2022 · 1 investors · BiotechnologyRule 506(b)
▶$30MraisedNov 2022 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Laura Sepp-LorenzinoDirector
- RA Session IIExecutive Officer, Director
- Kathleen ReapeDirector
- Kamran AlamExecutive Officer
- Phillip B. DonenbergDirector
- Paul B. ManningDirector
- Sean P. NolanDirector
- Suyash PrasadExecutive Officer
- Sukumar NagendranDirector
- Offering amount
- $30M
- Amount sold
- $30M
- First sale
- Oct 2022
- Incorporated
- Corporation, Delaware, 2020
- Federal exemptions
- 06b
▶$96MraisedAug 2020 · 26 investors · BiotechnologyRule 506(b)
▶$96MraisedAug 2020 · 26 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Sean NolanDirector
- Sukumar NagendranDirector
- Suyash PrasadExecutive Officer
- Kamran AlamExecutive Officer
- R. A. Session IIExecutive Officer, Director
- Paul B. ManningDirector
- Offering amount
- $96M
- Amount sold
- $96M
- First sale
- Jul 2020
- Incorporated
- Corporation, Delaware, 2020
- Federal exemptions
- 06b
▶$18MraisedMay 2020 · 9 investors · BiotechnologyRule 506(b)
▶$18MraisedMay 2020 · 9 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- R.A. Session IIExecutive Officer, Director
- Paul B. ManningDirector
- Sean NolanDirector
- Offering amount
- $30M
- Amount sold
- $18M
- Finders' fees
- $435K
- Placement agents
- Chardon Capital Markets LLC
- First sale
- Mar 2020
- Incorporated
- Corporation, Delaware, 2019
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 5
by search overlap
Seeking Alpha29 shared keywordsSeeking Alpha is a financial research platform offering stock analysis, market news, investment ideas, and quantitative ratings across asset classes, drawing on a large community of contributing analysts. It serves individual and professional investors seeking research and data-driven insight on stocks and markets.
Simply Wall St24 shared keywordsSimply Wall St is an investment platform that provides financial data visualization and analysis tools for individual investors. The platform serves long-term investors globally by simplifying complex market information into visual and narrative formats to make stock investing more accessible.
Robinhood24 shared keywordsRobinhood is a financial trading platform that enables users to manage portfolios across stocks, ETFs, cryptocurrencies, options, futures, and prediction markets. The platform serves retail investors with low barriers to entry, offering portfolio management services and market insights.
TradingView21 shared keywordsTradingView is a charting platform and social network used by over 100 million traders and investors worldwide to analyze and trade across global financial markets. The platform provides tools for technical analysis, market data, and community collaboration for retail and institutional traders.
StockTwits21 shared keywordsStocktwits operates an online community platform where investors and traders share ideas, analysis, and trade discussions organized around stock tickers. The page presented is its community guidelines rather than a product description.
Companies competing with Taysha Gene Therapies for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Taysha Gene Therapies (TSHA) raises $215.6M as losses widen in Q2 2026stocktitan.net · Aug 2026Frequently asked questions
- What does Taysha Gene Therapies do?
- Taysha Gene Therapies develops and commercializes gene therapies for monogenic diseases of the central nervous system, serving patients with rare and larger CNS conditions. Its lead clinical program targets Rett syndrome, alongside a broader pipeline of CNS programs.
- Who founded Taysha Gene Therapies?
- Taysha Gene Therapies was founded by R.A. Session II in 2019.
- Who are Taysha Gene Therapies's investors?
- Taysha Gene Therapies's investors include GV (Google Ventures), Baird, Goldman Sachs, Jefferies, PBM Capital.
- How much funding has Taysha Gene Therapies raised?
- Taysha Gene Therapies has disclosed $494M raised across 5 of its 6 known rounds.
- Where is Taysha Gene Therapies headquartered?
- Taysha Gene Therapies is headquartered in Texas, US.